ArticleFrontiers in oncology2026

LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy.

Juan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.